Phreesia, Inc.

NYSE:PHR

Medical - Healthcare Information Services

Healthcare
$12.26 +0.80%

+$0.08 today

Market cap
$760.99M
Beta
0.88
P/E (TTM)
62.6
EPS (TTM)
$0.15
52W Low $7.77High $32.76

Volume 0.86M

Average 1.97M

PHR Change in Working Capital

Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.

Phreesia, Inc.NYSE: PHR

Change in Working Capital · Q1 FY2027 · quarter ended Apr 2026

Change in working capital dips below year-ago levels

Q1 FY2027 change in working capital of $3.8M (cash outflow) fell 39.1% year over year, behind the +50.9% change in trailing-twelve-month change in working capital. Over 3 fiscal years it compounded at +53.9% a year.

Context

  • Change in working capital amounted to 2.9% of revenue in FY2026, up 1.4 pp from a year earlier.
  • Change in working capital grew in size in 2 of the last 3 fiscal years.
  • FY2026 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -39.1% toward the trailing-twelve-month pace of +50.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterApr 2026
-$3.8M-127.9% QoQ
Last fiscal yearJan 2026
-$14.09M+117.0% YoY
LTMApr 2026
-$11.16M+50.9% YoY
Change in Working Capital past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-39.1%——
1 year+117.0%——
3-year CAGR+53.9%——
5-year CAGR——
10-year CAGR——

Change in Working Capital history

USD · from the cash flow

Latest · FY2026
(14.09M) USD
Year-over-year change
-117.0%

Change in Working Capital vs competitors

How PHR compares with its peers on the latest reported figures

  • PHR's LTM Apr 2026 change in working capital of $11.16M is the 5th largest of the 11 companies compared; the peer median is $4.95M.
  • Its year-over-year change of +50.9% is the 4th highest of 10, against a peer median of -30.2%.
  • Change in working capital amounts to 2.3% of revenue for PHR, versus a peer median of 3.1%.
PHR Competitors Peer median
Change in Working Capital for PHR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GDRXGoodRx Holdings, Inc.LTM Mar 2026$42.39M -9.2%+40.6%5.4%
NEOGNeogen CorporationLTM Aug 2026$32.23M -30.2%—3.6%
SDGRSchrödinger, Inc.LTM Sep 2026$13.47M -112.7%—5.0%
BLFSBioLife Solutions, Inc.LTM Mar 2026$12.03M —-15.8%12.1%
PHRPhreesia, Inc.LTM Apr 2026$11.16M +50.9%+53.9%2.3%
KMTSKestra Medical Technologies, Ltd.LTM Jan 2026$6.61M +17305.3%—7.9%
ESTAEstablishment Labs Holdings Inc.LTM Sep 2026$6.56M -65.8%-15.1%2.5%
TDOCTeladoc Health, Inc.LTM Mar 2026$5.93M +123.8%—0.2%
OMCLOmnicell, Inc.LTM Mar 2026$3.35M -74.9%-51.6%0.3%
OMDAOmada HealthLTM Mar 2026$1.57M -87.6%—0.6%
NVCRNovoCure LimitedLTM Mar 2026$653K +111.0%—0.1%
Peer median (excluding PHR) $4.95M-30.2%-15.4%3.1%

Competitors are the stored peer set for PHR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2022
Jan 2022
FY2023
Jan 2023
FY2024
Jan 2024
FY2025
Jan 2025
FY2026
Jan 2026
Net Income(118.16M)(176.15M)(136.89M)(58.53M)2.31M
Depreciation & Amortization21.3M25.3M29.49M27.89M31.45M
Deferred Income Tax143K434K228K214K(13.27M)
Stock-Based Compensation36.14M58.78M71.7M66.98M67.45M
Change in Working Capital(18.57M)(3.86M)(1.64M)(6.49M)(14.09M)
Accounts Receivables(10.22M)(11.13M)(11.21M)(8.81M)(10.15M)
Inventory00000
Accounts Payables2.88M4.77M(1.99M)(3.23M)5.26M
Other Working Capital(11.24M)2.5M11.56M5.55M(9.2M)
Other Non-Cash Items4.43M5.37M4.73M2.33M4.96M
Operating Cash Flow(74.71M)(90.12M)(32.38M)32.38M78.81M
Capital Expenditures(30.81M)(26.2M)(25.1M)(24.09M)(11.1M)
Acquisitions (Net)(34.42M)0(14.57M)0(153.19M)
Purchases of Investments000015.71M
Sales of Investments00000
Other Investing Activities(12.39M)(21.47M)(19.29M)(15.38M)(13.3M)
Investing Cash Flow(65.23M)(26.2M)(39.67M)(24.09M)(161.88M)
Debt Repayment(4.27M)(5.95M)(6.78M)(7.81M)83.18M
Common Stock Issued245.81M4.92M03.93M3.83M
Common Stock Repurchased(9M)(19.38M)(12.18M)00
Dividends Paid00000
Other Financing Activities2.42M(397K)1.84M(7.61M)(14.15M)
Financing Cash Flow234.97M(20.8M)(17.12M)(11.49M)72.85M
Effect of Forex Changes000(106K)(176K)
Net Change in Cash95.03M(137.13M)(89.16M)(3.3M)(10.39M)
Free Cash Flow(105.52M)(116.33M)(57.48M)8.29M67.71M

Phreesia, Inc.

NYSE:PHR

Intrinsic Alpha fair value

Locked

Current Price

$12.26

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.